Society for Translational Oncology


Highlights from STO's educational activities, including content associated with the Society and its journal The Oncologist. RSS Feed URL

Society for Translational Oncology navigateright Episode

Molecular Tumor Board: Resistance to Checkpoint Inhibitors - Part 1

David Liu, MD, MPH, MS 
Massachusetts General Hospital

Video Overview:
Lecture Slides

The development of immune checkpoint blockade (ICB) has revolutionized the treatment of cancer. However, the ability to identify which patients will have durable benefit and to understand how tumors develop resistance to ICB is critical to improving patient management and outcomes. Here, we present two complementary approaches representing parallel paths to dissecting response and resistance to ICB.

These lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.